Our group constructed a predictive model based on pre-treatment PBMCs of HCC patients and concluded that existence of pre-activated PD-1+ and Tim-3+CD8+ T cells with homing capability (CCR5+ and CXCR6+) was key in predicting response to Y-90-RE (22). The gene discussed is HAVCR2; the disease is hepatocellular carcinoma.